[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Bachanova et al., 2014 - Google Patents

NK cells in therapy of cancer

Bachanova et al., 2014

View HTML
Document ID
10234773693431614545
Author
Bachanova V
Miller J
Publication year
Publication venue
Critical Reviews™ in Oncogenesis

External Links

Snippet

Natural killer (NK) cells recognize targets stressed by malignant transformation or infection and can be long-lived. They become educated by interacting with major histocompatibility antigen (MHC) class I molecules to gain function to kill targets and produce cytokines. In the …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Bachanova et al. NK cells in therapy of cancer
Shimasaki et al. NK cells for cancer immunotherapy
Ames et al. Advantages and clinical applications of natural killer cells in cancer immunotherapy
Miller et al. Natural killer cells in cancer immunotherapy
Dolstra et al. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients
Parkhurst et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
Minetto et al. Harnessing NK cells for cancer treatment
Ljunggren et al. Prospects for the use of NK cells in immunotherapy of human cancer
Suen et al. Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials
Lamb et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Geller et al. Use of allogeneic NK cells for cancer immunotherapy
Rossi et al. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
Tonn et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92
Sosman et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells
Scheper et al. Cancer immunotherapy using γδT cells: dealing with diversity
Davies et al. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Berrien-Elliott et al. Improving natural killer cell cancer immunotherapy
Bodduluru et al. Natural killer cells: the journey from puzzles in biology to treatment of cancer
Spel et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
Zaghi et al. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy
Introna et al. Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms
Locatelli et al. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
Cui et al. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma
Mata-Molanes et al. Cancer immunotherapy with cytokine-induced killer cells
Norell et al. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias